Answer:
The evidence suggests that these chloroplast organelles were also once free-living bacteria.
Explanation:
The endosymbiotic event that generated mitochondria must have happened early in the history of eukaryotes, because all eukaryotes have them.
:)
<span>Most organisms, including humans, can't use the free gaseous form of nitrogen found in the air. We need other organisms and natural processes to "fix" nitrogen into a solid form that plants and animals can use. Most of the nitrogen that plants and animals use is made by bacteria.</span>
The answer would be conservative plate boundaries.
They occur where plates slide past each other in opposite directions, or in the same direction but at different speeds. Friction is eventually overcome and the plates slip past in a sudden movement. The shockwaves created produce an earthquake.
I hope this helped and is correct! :)
Speciation<span> is the </span>evolutionary<span> process by which biological populations evolve to become distinct </span>species<span>. The biologist </span>Orator F. Cook<span> coined the term 'speciation' in 1906 for the splitting of lineages or "</span>cladogenesis," as opposed to "anagenesis<span>" or "phyletic evolution" within lineages.</span>
Answer:
Phase III
Explanation:
The given condition fall in the trial phase (Phase III) of cinical study which aims to:
- Determine drug's effectiveness (primary goal)
- Determine long-term drug safety
- Confirm findings
In Phase III, randomised, double-blind, placebo-controlled, parallel group study is majorly to evaluate the efficacy and safety of placebo in episodic migraine prevention in children (6 to < 12 years of age) and adolescents (12 to < 18 years of age).
The trial consists of four phases: screening; double-blind therapy period for 24 weeks in which placebo or Erenumab is given to subject as dose 1, dose 2 or dose 3 (based on the participant's body weight) once a month via subcutaneous injection; optional dose level blinded extension phase (40 weeks) which involves subjects recieve dose1, 2 and 3 of placebo, and at last it follows a safety follow-up phase for 12 weeks (after 16 weeks of the last dose of investigational drug).
Hence, the clinical phase is phase III.
